UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1034-13
Program Prior Authorization/Notification
Medication Mytesi™ (crofelemer)
P&T Approval Date 2/2013, 11/2013, 2/2015, 2/2016, 2/2017, 2/2018, 2/2019, 2/2020,
2/2021, 2/2022, 2/2023, 2/2024, 2/2025
Effective Date 5/1/2025
1. Background:
Mytesi (crofelemer) is an anti-diarrheal indicated for the symptomatic relief of non-infectious
diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. Ruling out infectious
etiologies of diarrhea is required for the appropriate use of Myesi.1
Members will be required to meet the coverage criteria below.
2. Coverage Criteriaa:
A. Initial Authorization
1. Mytesi will be approved based on all of the following criteria:
a. Diagnosis of HIV/AIDS associated diarrhea
-AND-
b. Patient is on antiretroviral therapy
Authorization will be issued for 12 months.
B. Reauthorization
1. Mytesi will be approved based on the following criterion:
a. Documentation of positive clinical response to Mytesi therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
© 2025 UnitedHealthcare Services, Inc.
1
• Supply limits may be in place.
4. Reference:
1. Mytesi [package insert]. San Francisco, CA: Napo Pharmaceuticals, Inc; November 2020.
Program Prior Authorization/Notification - Mytesi (crofelemer)
Change Control
2/2013 New criteria.
11/2013 Formatting update. Removal of dose information in Background
Section. Updated reference.
9/2014 Administrative change - Tried/Failed exemption for State of New Jersey
removed.
2/2015 Minor formatting.
2/2016 Annual review. Updated criteria to reflect indications and usage section
of product label.
2/2017 Annual review. Program updated to reflect change in brand name from
Fulyzaq to Mytesi. No change in clinical coverage. Updated reference.
2/2018 Annual review. No change in clinical coverage.
2/2019 Annual review. No change in clinical coverage. Updated reference.
2/2020 Annual review. No change in clinical coverage.
2/2021 Annual review. No change in clinical coverage. Updated reference.
2/2022 Annual review with no changes to coverage criteria. Updated
background.
2/2023 Annual review with no changes to coverage criteria. Added state
mandate footnote.
2/2024 Annual review with no changes to coverage criteria.
2/2025 Annual review. Updated initial authorization duration to 12 months.
© 2025 UnitedHealthcare Services, Inc.
2